The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Astellas

Cardiome Licenses Vernakalant (Oral) to Merck

Merck & Co., Inc. and Cardiome Pharma Corp. announced a collaboration and license agreement that provides Merck with exclusive global rights to the oral formulation of vernakalant for the maintenance of normal heart rhythm in patients with atrial fibrillation. Here’s the deal: US$60 million upfront up to US$200 million in development and approval milestones up [...]

CV Therapeutics – Going Once, Going Twice…

… Sold to the Knight in White for $1.4 billion? With Astellas announcing this morning that they will not be outbidding Gilead for CV Therapeutics, the share price dropped back down slightly below Gilead’s $20 per share offer price, indicating that investors don’t see another bidder materializing.

M&A! Hooray! Genentech’s and CV Therapeutics’ Dreams Come True

Seems like $95 per share was the magic number for Genentech, which finally succumbed to Roche’s persistent advances; and in other new news… CV Therapeutics‘ (Nasdaq: CVTX) found a White Knight in Gilead Sciences, which will pay $1.4 billion ($20/share), topping Astellas’ $16/share offer, which CV Therapeutics rejected a few weeks ago.  Pre-market trading is [...]

M&A Update 2

Here’s the latest collection of M&A news we’ve found since the last update.  No new mega-deals, although Sanofi is shopping in the €15 billion range and Roche sold $16 billion of debt (which has seen high demand in subsequent trading) in the largest offering ever to raise cash for its Genentech bid.  Also, CV Therapeutics‘ (Nasdaq: CVTX) Board [...]

It’s Raining M&A

Pfizer-Wyeth is certainly the biggest headline (see here for info on those companies in Canada), but it seems like a very popular time to be shopping.

Follow

Get every new post delivered to your Inbox.

Join 84 other followers